🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in Canada / NCT05074342
Enrolling by invitation Observational

Project Open - Use of Administrative Health Data to Increase Diabetic Retinopathy Screening

NCT05074342 · tracked via the Priya Life Science Canada tracker
Phase
Observational
Started
2022-02-01
Last updated
2025-04-01

Condition(s) studied

DiabetesDiabetic Retinopathy

Study summary

Early detection through regular diabetic retinopathy screening (DRS) is an effective method of preventing vision loss by enabling earlier intervention and timely treatment. It is recommended that all people with diabetes receive regular DRS, either annually or bi-annually. Current DRS practice in Canada, however, falls remarkably short of recommended DRS rates resulting in preventable vision loss.

In this project the investigators use population health-based approach to diabetes care. Linked provincial administrative data will be leveraged to consistently identify all those that have not had DRS in 425 days with the goal to improve outcomes, equity and potentially reduce the cost of care delivery.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. At least 18 years of age 2. Type 1 or type 2 diabetes as determined through linked provincial healthcare administrative datasets or primary care data using algorithms similar to provincial methods. 3. Attended the primary health care setting, with at least 1 visit to the centre within the past 10 years Exclusion Criteria: 1\. Individuals identified as having received DRS (in the previous 425 days) by an ophthalmologist and/or optometrist or tele-ophthalmology/Tele-Retina.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
University Health Network Toronto Ontarioa

More University Health Network, Toronto trials in Canada

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05074342 on ClinicalTrials.gov ↗ ← All trials in Canada